March-in Rights

C4IP Letter to Senate Judiciary Committee on 5/21 Hearing on Drug Prices, 5/20/2024

Op-ed: Judge Paul Michel, “Biden’s shortsighted patent attacks threaten American innovation,” The Hill, 6/4/2024

C4IP Comments RE: Unlocking the Full Potential of Intellectual Property by Translating More Innovation to the Marketplace (PTO-C-2024-0004), 5/13/2024

Op-ed: Dana Colarulli, “President Biden, Don’t Undo Your Innovation Legacy,” RealClearHealth, 5/2/2024

Issue Brief: The Bayh-Dole Act and March-In Rights, December 2023

What IP Experts Are Saying About the Biden Administration’s Draft Framework for March-In Rights, February 2024

Blog: Fact Check: Misusing the Bayh-Dole Act’s March-In Rights is Not an Effective Way to Reduce Drug Prices, 1/29/2024

Briefing: The Bayh-Dole Act and March-In Rights, 1/24/2024

Blog: Fact Check: The Bayh-Dole Act Does Not Impede Knowledge Sharing, 6/16/2023

Op-ed: Andrei Iancu and David Kappos, “New Yorkers should be concerned about Biden proposal on academic research,” The Buffalo News, 4/8/2024

Op-ed: Amir Naiberg and Andrei Iancu, “Biden administration proposal threatens innovative research at universities across the country,” The Orange County Register, 4/1/2024

Op-ed: Andrei Iancu and David Kappos, “‘March-in’ rights: Why Biden’s changes contradict the point of the Bayh-Dole Act,” World IP Review, 2/15/2024

Scroll to Top